Loading clinical trials...
Loading clinical trials...
Standard Chemotherapy Plus Oral Everolimus as Adjuvant Therapy for LAR Breast Cancer Patients: A Randomized, Open-Label, Phase III Trial （POLARIS）
Conditions
Interventions
Everolimus 10 mg daily
Start Date
February 1, 2026
Primary Completion Date
February 1, 2033
Completion Date
February 1, 2033
Last Updated
February 12, 2026
NCT06547840
NCT07378319
NCT06649331
NCT07029399
NCT06878248
NCT06189209
Lead Sponsor
Fudan University
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions